Sherman Oaks biopharmaceutical company T-Cure Bioscience has entered into a license agreement with Chinese biotech Immunotech Biopharm Ltd. to develop a T cell therapy for renal cancer, the companies announced Wednesday. ...

Subscribe to get the full story.


Are you a subscriber? Sign In